Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study

被引:5
作者
Drabik, Attyla [1 ]
Sturm, Andreas [2 ]
Bloemacher, Margit [3 ]
Helwig, Ulf [4 ]
机构
[1] Clin Trial Support, Munster, Germany
[2] DRK Kliniken Berlin Westend, Dept Gastroenterol, Berlin, Germany
[3] Kompetenznetz Darmerkrankungen eV, Kiel, Germany
[4] Med Practice Internal Med Oldenburg, Neue Donnerschweer Str 30, D-26123 Oldenburg, Germany
关键词
ulcerative colitis; golimumab; fecal calprotectin; tumor necrosis factor alpha;
D O I
10.2196/resprot.5791
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The treatment of ulcerative colitis (UC) patients with moderate to severe inflammatory activity with anti-tumor necrosis factor alpha (TNF alpha) antibodies leads to a clinical remission rate of 10% after 8 weeks of therapy. However, it must be taken into account that patient selection in clinical trials clearly influences both response and remission rates. An unsatisfactory response to anti-TNF alpha medication after week 12 often leads to a discontinuation of treatment. The early prediction of clinical response could therefore help optimize therapy and potentially avoid ineffective treatments. Objective: The aim of this study is to develop an algorithm for optimizing golimumab administration in patients with moderate to severe UC by calculating the probability of clinical response in Week 26 based on data from Week 6. Methods: The study is designed as a prospective, single-arm, multicenter, non-interventional observational study with no interim analyses and a sample size of 58 evaluable patients. The primary outcome is the prediction of clinical response in Week 26 based on a 50% reduction in fecal calprotectin and a positive golimumab trough level in Week 6. Results: Enrollment started in October 2014 and was still open at the date of submission. The study is expected to finish in December 2016. Conclusions: The early identification of patients who are responding to an anti-TNF alpha antibody is therapeutically beneficial. At the same time, patients who are not responding can be identified earlier. The development of a therapeutic algorithm for identifying patients as responders or non-responders can thus help prescribing physicians to both avoid ineffective treatments and adjust dosages when necessary. This in turn promotes a higher degree of treatment tolerance and patient safety in the case of anti-TNF alpha antibody administration.
引用
收藏
页数:8
相关论文
共 11 条
[1]
Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding [J].
Angelberger, Sieglinde ;
Reinisch, Walter ;
Messerschmidt, Agnes ;
Miehsler, Wolfgang ;
Novacek, Gottfried ;
Vogelsang, Harald ;
Dejaco, Clemens .
JOURNAL OF CROHNS & COLITIS, 2011, 5 (02) :95-100
[2]
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial [J].
Cornillie, Freddy ;
Hanauer, Stephen B. ;
Diamond, Robert H. ;
Wang, Jianping ;
Tang, Kezhen L. ;
Xu, Zhenhua ;
Rutgeerts, Paul ;
Vermeire, Severine .
GUT, 2014, 63 (11) :1721-1727
[3]
De VM, 2012, J CROHNS COLITIS, V6, P557
[4]
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Publication with Expression of Concern) [J].
Dignass, Axel ;
Lindsay, James O. ;
Sturm, Andreas ;
Windsor, Alastair ;
Colombel, Jean-Frederic ;
Allez, Mathieu ;
D'Haens, Gert ;
D'Hoore, Andre ;
Mantzaris, Gerassimos ;
Novacek, Gottfried ;
Oeresland, Tom ;
Reinisch, Walter ;
Sans, Miquel ;
Stange, Eduard ;
Vermeire, Severine ;
Travis, Simon ;
Van Assche, Gert .
JOURNAL OF CROHNS & COLITIS, 2012, 6 (10) :991-1030
[5]
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents [J].
Molander, Pauliina ;
af Bjorkesten, Clas-Goran ;
Mustonen, Harri ;
Haapamaki, Johanna ;
Vauhkonen, Matti ;
Kolho, Kaija-Leena ;
Farkkila, Martti ;
Sipponen, Taina .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (11) :2011-2017
[6]
Panaccione R, 2011, ECCO M 2011 INFL AZ
[7]
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial [J].
Reinisch, Walter ;
Sandborn, William J. ;
Hommes, Daniel W. ;
D'Haens, Geert ;
Hanauer, Stephen ;
Schreiber, Stefan ;
Panaccione, Remo ;
Fedorak, Richard N. ;
Tighe, Mary Beth ;
Huang, Bidan ;
Kampman, Wendy ;
Lazar, Andreas ;
Thakkar, Roopal .
GUT, 2011, 60 (06) :780-787
[8]
Infliximab for induction and maintenance therapy for ulcerative colitis [J].
Rutgeerts, P ;
Sandborn, WJ ;
Feagan, BG ;
Reinisch, W ;
Olson, A ;
Johanns, J ;
Travers, S ;
Rachmilewitz, D ;
Hanauer, SB ;
Lichtenstein, GR ;
de Villiers, WJS ;
Present, D ;
Sands, BE ;
Colombel, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2462-2476
[9]
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis [J].
Sandborn, William J. ;
Feagan, Brian G. ;
Marano, Colleen ;
Zhang, Hongyan ;
Strauss, Richard ;
Johanns, Jewel ;
Adedokun, Omoniyi J. ;
Guzzo, Cynthia ;
Colombel, Jean-Frederic ;
Reinisch, Walter ;
Gibson, Peter R. ;
Collins, Judith ;
Jarnerot, Gunnar ;
Hibi, Toshifumi ;
Rutgeerts, Paul .
GASTROENTEROLOGY, 2014, 146 (01) :85-95
[10]
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis [J].
Sandborn, William J. ;
Feagan, Brian G. ;
Marano, Colleen ;
Zhang, Hongyan ;
Strauss, Richard ;
Johanns, Jewel ;
Adedokun, Omoniyi J. ;
Guzzo, Cynthia ;
Colombel, Jean-Frederic ;
Reinisch, Walter ;
Gibson, Peter R. ;
Collins, Judith ;
Jarnerot, Gunnar ;
Rutgeerts, Paul .
GASTROENTEROLOGY, 2014, 146 (01) :96-+